ARTICLE | Company News
Paion, Cosmo deal
July 18, 2016 7:00 AM UTC
Paion granted Cosmo’s Cosmo Technologies Ltd. subsidiary exclusive U.S. rights to develop and commercialize remimazolam, an ultra-short-acting GABA A receptor modulator. ...
Paion granted Cosmo’s Cosmo Technologies Ltd. subsidiary exclusive U.S. rights to develop and commercialize remimazolam, an ultra-short-acting GABA A receptor modulator. ...